Next Generation Cancer Diagnostics Market, By Technology (RT-PCR, Next Generation Sequencing, DNA Microarray, Lab-on–a-chip and Others), By Cancer Type (Lung cancer, Prostate cancer, Breast cancer, Colorectal cancer and Others), By Application (CTC Analysis, Biomarker, Proteomic Analysis and Others) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030

Report Code: PMI474821 | Publish Date: May 2023 | No. of Pages: 192

Global Next Generation Cancer Diagnostics Market Overview

NGS is perhaps one of the most important technological developments in the biological sciences in the last 30 years. Given the hereditary Technology’s of cancer, medical research has embraced technology, and the cancer sector is at the forefront of these efforts. Global efforts to catalogue mutations in a variety of cancer types are underway, and new discoveries are expected to lead to new diagnostic, prognostic, and therapeutic targets. NGS has progressed to the point that several laboratories are considering it for routine diagnostic application. NGS has been widely used in the research community for de novo genome sequencing, DNA resequencing, transcriptome sequencing, and epigenomics. These studies have paved the way for the development of novel procedures (both in the molecular and bioinformatic contexts) as well as a better understanding of the technology's primary strengths and drawbacks. The International Genome Consortium (ICGC) and The Cancer Genome Atlas (TCGA) project are using next-generation sequencing to catalogue the genomic landscape of thousands of cancer genomes across a variety of disease types. NGS refers to a group of technologies that can sequence millions of DNA templates in a massively parallel fashion The Global Next Generation Cancer Diagnostics Market accounted for US$ 5650.9 Million 2020 and is estimated to be US$ 28,746.19 million by 2030 and is anticipated to register a CAGR of 19.8%.

Global Next Generation Cancer Diagnostics Market Dynamics

                                                   

 

                                                       

Growth in business operations by emerging and small sized players

The demand for next-generation cancer diagnostic tests is expected to increase as the frequency of oncology disorders rises. These tests are projected to aid early detection and efficient prognosis of many types of cancer, favorably impacting the growth of this vertical over the forecast period. A prominent element projected to give lucrative growth possibilities for this market is the development and introduction of product offerings by a number of large businesses. The market is characterized by potentially high-value avenues and prospects for growth during the projected period, as the development of companion diagnostics for their use in delivering personalized and advanced genomic medicine accelerates.

Challenges

Due to increased costs, lower reimbursement rates, and budgetary constraints, many hospitals in poorer nations are unable to invest in diagnostic imaging technology. However, because of the increasing demand for diagnostic imaging operations in these countries, hospitals that cannot afford to purchase new imaging equipment choose to use secondhand systems. Refurbished systems are less expensive than new systems, costing about 40% to 60% less. As a result, a growing number of industry leaders are promoting refurbished gadgets through various schemes. Siemens' Medical Proven Excellence Program, GE Healthcare's Gold Seal Program, and Philips' Diamond Select Program, for example, are three well-known global refurbishing programmes that encourage the use of reconditioned diagnostic imaging systems.

Access Crucial Insights at a Fraction of the Cost | Request Your Discount

Global Next Generation Cancer Diagnostics Market Segmentation

                                                   

The global Next Generation Cancer Diagnostics market is segmented based on technology, cancer type, application and region.

On the basis of Technology, the global Next Generation Cancer Diagnostics market is segmented into RT-PCR, Next Generation Sequencing, DNA Microarray, Lab-on–a-chip and Others. Based on Cancer Type, the target market is segmented into Lung cancer, Prostate cancer, Breast cancer, Colorectal cancer and Others. By Application, the market is segmented into CTC Analysis, Biomarker, Proteomic Analysis and Others.

Regional Insights:

                                                   

On region the global Next Generation Cancer Diagnostics market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to dominate the Next Generation Cancer Diagnostics market. This is mainly attributed due to factors such as increasing incidence of cancer and technological advancement. Asia Pacific is likely to be one of the fastest-growing regions in this industry, with a promising future. A largely untapped market base, which has shown technological development in healthcare research over the last decade, is one factor accounting for higher growth.

                                             

Reduce costs by up to 30% with a custom report tailored to your specific needs | Request Customized Report

Report Scope:

Attribute

Details

Base year for estimation

2020

Forecast period

2020 – 2030

Market representation

Revenue in USD Million & CAGR from 2020 – 2030

Market Segmentation

By Technology- RT-PCR, Next Generation Sequencing, DNA Microarray, Lab-on–a-chip and Others.

By Cancer Type– Lung cancer, Prostate cancer, Breast cancer, Colorectal cancer and Others.

By Application- CTC Analysis, Biomarker, Proteomic Analysis and Others.

Regional scope

North America - U.S., Canada

Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe

Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific

Latin America - Brazil, Mexico, Argentina, Rest of Latin America

Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2020 to 2030. For the purpose of this study, has segmented the global Next Generation Cancer Diagnostics market report based on technology, cancer type, application and region.

                                               

Global Next Generation Cancer Diagnostics Market, By Region:

      • North America
          • U.S.
          • Canada
      • Europe
          • Germany
          • UK
          • France
          • Russia
          • Italy
          • Rest of Europe
      • Asia Pacific
          • China
          • India
          • Japan
          • South Korea
          • Rest of Asia Pacific
      • Latin America
          • Brazil
          • Mexico
          • Rest of Latin America
      • Middle East & Africa
          • GCC
          • Israel
          • South Africa
          • Rest of Middle East & Africa

Global Next Generation Cancer Diagnostics Market Key Players

The key players operating in the global Next Generation Cancer Diagnostics market includes Koninklijke Philips N.V., Illumina, Inc.,   F. Hoffmann-La Roche Ltd, Qiagen, Cepheid, Novartis AG, Abbott, Thermo Fisher Scientific, Inc., Sysmex Corporation Opko Health, Inc., Myriad Genetics, Inc., Agilent Technologies, GE Healthcare, PerkinElmer, Inc., Genomic Health, Inc., Hologic, Inc., Almac Group, Janssen Global Services, LLC and Myriad Genetics.

Global Next Generation Cancer Diagnostics Market Company Profile

  • Koninklijke Philips N.V.*
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Illumina, Inc.
  • F. Hoffmann-La Roche Ltd
  • Qiagen
  • Cepheid
  • Novartis AG
  • Abbott
  • Thermo Fisher Scientific, Inc.
  • Sysmex Corporation Opko Health, Inc.
  • Myriad Genetics, Inc.
  • Agilent Technologies
  • GE Healthcare
  • PerkinElmer, Inc.
  • Genomic Health, Inc.
  • Hologic, Inc.
  • Almac Group
  • Janssen Global Services, LLC
  • Myriad Genetics

“*” marked represents similar segmentation in other categories in the respective section

Global Next Generation Cancer Diagnostics Market Table of Contents

  • Research Objective and Assumption
    • Preface
    • Research Objectives
    • Study Scope
    • Years Considered for the study
    • Assumptions
    • Abbreviations
  • Research Methodology
    • Research data
    • Primary Data
      • Primary Interviews
      • Primary Breakdown
      • Key data from Primary Sources
      • Key Thickness Insights
    • Secondary Data
      • Major Secondary Sources
      • Secondary Sources
    • Market Estimation
    • Top-Down Approach
      • Approach for estimating Market Share by Top-Down Analysis (Supply Side)
    • Bottom-Up Approach
      • Approach for estimating market share by Bottom-up Analysis (Demand Side)
    • Market Breakdown and Data Triangulation
    • Research Assumptions
  • Market Purview
    • Executive Summary
    • Key Findings—Global Outlook for Next Generation Cancer Diagnostics Strategies
      • Key Questions this Study will Answer
      • Market Snippet, By Technology
      • Market Snippet, By Cancer Type
      • Market Snippet, By Application
      • Market Snippet, By Region
    • Opportunity Map Analysis
    • Executive Summary—3 Big Predictions
  • Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
      • Market Trends
    • DR Impact Analysis
    • PEST Analysis
    • Porter’s Five Forces Analysis
    • Opportunity Orbit
    • Market Investment Feasibility Index
    • Macroeconomic Factor Analysis
  • Global Next Generation Cancer Diagnostics Market, By Technology, 2020 – 2030, (US$ Mn)
    • RT-PCR
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Segment Trends
    • Next Generation Sequencing
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • DNA Microarrays
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Lab-on-a-Chip
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Others
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
  • Global Next Generation Cancer Diagnostics Market, By Cancer Type, 2020 – 2030, (US$ Mn)
    • Lung cancer
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Segment Trends
    • Prostate cancer
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Breast cancer
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Colorectal cancer
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Others
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
  • Global Next Generation Cancer Diagnostics Market, By Application, 2020 – 2030, (US$ Mn)
    • CTC Analysis
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Segment Trends
    • Biomarkers
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Proteomic Analysis
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Others
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
  • Global Next Generation Cancer Diagnostics Market, By Region, 2020 – 2030, (US$ Mn)
    • Overview
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Regional Trends
    • North America
      • Market Size and Forecast (US$ Mn), By Technology, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Cancer Type, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Application, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast (US$ Mn), By Technology, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Cancer Type, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Application, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • Germany
        • UK
        • France
        • Russia
        • Italy
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast (US$ Mn), By Technology, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Cancer Type, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Application, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • China
        • India
        • Japan
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast (US$ Mn), By Technology, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Cancer Type, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Application, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East & Africa
      • Market Size and Forecast (US$ Mn), By Technology, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Cancer Type, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Application, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • GCC
        • Israel
        • South Africa
        • Rest of Middle East
  • Competitive Landscape
    • Heat Map Analysis
    • Market Presence and Specificity Analysis
  • Company Profiles
  • Koninklijke Philips N.V.*
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Illumina, Inc.
  • F. Hoffmann-La Roche Ltd
  • Qiagen
  • Cepheid
  • Novartis AG
  • Abbott
  • Thermo Fisher Scientific, Inc.
  • Sysmex Corporation Opko Health, Inc.
  • Myriad Genetics, Inc.
  • Agilent Technologies
  • GE Healthcare
  • PerkinElmer, Inc.
  • Genomic Health, Inc.
  • Hologic, Inc.
  • Almac Group
  • Janssen Global Services, LLC
  • Myriad Genetics

The Last Word

    • Future Impact
    • About Us
    • Contact

FAQs

The global Next Generation Cancer Diagnostics market is segmented based on technology, cancer type, application and region.

The demand for next-generation cancer diagnostic tests is expected to increase as the frequency of oncology disorders rises.

North America is expected to dominate the Next Generation Cancer Diagnostics market. This is mainly attributed due to factors such as increasing incidence of cancer and technological advancement.

The prominent players are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events, as their strategies in the market.